OZEMPIC Drug Patent Profile

When do Ozempic patents expire, and when can generic versions of Ozempic launch?

Ozempic is a drug marketed by Novo and is included in one NDA. There are seventeen patents protecting this drug and three Paragraph IV challenges.

This drug has two hundred and nine patent family members in thirty countries.

The generic ingredient in OZEMPIC is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Ozempic

Ozempic was eligible for patent challenges on December 5, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2031. This may change due to patent challenges or generic licensing.

There have been thirty-one patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OZEMPIC

International Patents:	209
US Patents:	17
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	41
Patent Applications:	1,420
Drug Prices:	Drug price information for OZEMPIC
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OZEMPIC
What excipients (inactive ingredients) are in OZEMPIC?	OZEMPIC excipients list
DailyMed Link:	OZEMPIC at DailyMed

See drug prices for OZEMPIC

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OZEMPIC

NDA:

209637

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OZEMPIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Minnesota	PHASE3
The Metis Foundation	PHASE3
First Affiliated Hospital of Wenzhou Medical University	PHASE2

See all OZEMPIC clinical trials

Pharmacology for OZEMPIC

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for OZEMPIC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OZEMPIC	Injection	semaglutide	2 mg/3 mL	209637	1	2024-04-11
OZEMPIC	Injection	semaglutide	8 mg/3 mL	209637	1	2022-12-21
OZEMPIC	Injection	semaglutide	2 mg/1.5 mL and 4 mg/3 mL	209637	7	2021-12-06

US Patents and Regulatory Information for OZEMPIC

OZEMPIC is protected by twenty US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019		RX	Yes	Yes			Y		Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-004	Oct 6, 2022		RX	Yes	Yes			Y		Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019		RX	Yes	Yes			Y		Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-003	Mar 28, 2022		RX	Yes	Yes			Y		Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019		RX	Yes	Yes			Y		Y

Expired US Patents for OZEMPIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-004	Oct 6, 2022
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-003	Mar 28, 2022
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-003	Mar 28, 2022
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019

EU/EMA Drug Approvals for OZEMPIC

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novo Nordisk A/S	Wegovy	semaglutide	EMEA/H/C/005422Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to	Authorised	no	no	no	2022-01-06
Novo Nordisk A/S	Ozempic	semaglutide	EMEA/H/C/004174Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2018-02-08
Novo Nordisk A/S	Rybelsus	semaglutide	EMEA/H/C/004953Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2020-04-03

International Patents for OZEMPIC

See the table below for patents covering OZEMPIC around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	200700433	Acylated glp-1 compounds
China	100571804
Poland	1863839
Croatia	P20251088
Taiwan	I842681

Supplementary Protection Certificates for OZEMPIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	C201830026	Spain		PRODUCT NAME: OZEMPIC-SEMAGLUTIDA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1251; DATE OF AUTHORISATION: 20180208; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1251; DATE OF FIRST AUTHORISATION IN EEA: 20180208
1863839	300936	Netherlands		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	SPC/GB18/023	United Kingdom		PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208
1863839	18C1017	France		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180212
1863839	132018000000262	Italy		PRODUCT NAME: SEMAGLUTIDE(OZEMPIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1251, 20180212

Market Dynamics and Financial Trajectory for OZEMPIC

Last updated: March 20, 2026

What is OZEMPIC and its primary therapeutic indication?

OZEMPIC (semaglutide) is a glucagon-like peptide-1 receptor agonist approved for managing type 2 diabetes mellitus (T2DM). It also has indications for obesity management. The drug is administered via once-weekly subcutaneous injection.

How does the market landscape for OZEMPIC develop?

Market size and growth drivers

• Global market for GLP-1 receptor agonists: Estimated at $17.5 billion in 2022, projected to reach $35.2 billion by 2028, growing at a compound annual growth rate (CAGR) of 12.0% (Fortune Business Insights, 2023).
• T2DM prevalence: Exceeds 400 million globally, with projections reaching over 600 million by 2040 (International Diabetes Federation, 2022).
• Obesity prevalence: Over 1.9 billion adults worldwide are overweight; roughly 650 million are obese, driving demand for weight management therapies (World Health Organization, 2022).

Competitive positioning

• OZEMPIC's main competitors include Trulicity (dulaglutide), Mounjaro (tirzepatide), and Victoza (liraglutide).
• Mounjaro, approved in 2022, is generating significant interest due to its dual GIP and GLP-1 activity, presenting a direct challenge.

Geographic expansion and reimbursement

• The drug has achieved regulatory approval in the US, Europe, and select Asian markets.
• Coverage varies; reimbursement policies influence sales, especially in cost-sensitive regions.

What are the financial trends observed for OZEMPIC?

Revenue performance

Year	Global Sales (USD billion)	Growth Rate	Source
2020	2.2	-	[1]
2021	3.4	54.5%	[1]
2022	4.9	44.1%	[1]
2023 (est.)	6.8	38.8%	Analyst estimates

• Sales increased sharply from 2020 to 2022, driven by expanding indications and geographic reach.
• The obesity indication launched in the US in June 2022 significantly contributed to revenue growth.

Future revenue projections

• 2024-2027: Expected to grow at a CAGR of 15-20%, with annual sales approaching or exceeding $15 billion by 2027.
• Main growth factors: Broader adoption for obesity, increased prescriber acceptance, and early entry into emerging markets.

Cost structure and profitability

• Research & Development: High, with approximately 25% of revenue reinvested annually.
• Margins: Operating margins in the range of 20-25% due to high R&D costs and marketing expenses.

How do regulatory developments influence the financial trajectory?

• New approvals and expanded indications increase market penetration.
• Pushback or delays in regulatory processes, especially in cost-sensitive markets, can temper growth.
• Health authorities (FDA, EMA) scrutinize pricing and reimbursement policies, impacting market access.

What are the key risks and opportunities?

Risks

• Competitive pressure from newer agents like tirzepatide.
• Regulatory restrictions over pricing.
• Supply chain issues affecting manufacturing and distribution.

Opportunities

• Expansion into new markets, including Latin America and Southeast Asia.
• Increasing acceptance of GLP-1 drugs for cardiovascular and renal protection.
• Development of fixed-dose combinations and formulations.

How has the financial performance of OZEMPIC influenced the parent company?

Novo Nordisk's financial impact

• Revenue contribution: OZEMPIC is a major revenue component for Novo Nordisk, accounting for nearly 30% of total sales in 2022.
• Profitability boost: Significant profit contribution, supporting investment in R&D and manufacturing capacity.
• Stock performance: Shares of Novo Nordisk increased substantially following OZEMPIC's sales growth announcements.

Summary of market and financial benchmarks

Metric	2020	2022	2023 (estimated)	Comments
Global GLP-1 market size	$17.5B	$17.5B	$19.5B	Growth driven by OZEMPIC and competitors
OZEMPIC sales (USD)	N/A	$4.9B	$6.8B	Rapid growth post-obesity approval
Market share in GLP-1 class	N/A	28%	32%	Increased due to product approval and acceptance

Key Takeaways

• OZEMPIC leads the GLP-1 class with rapid revenue growth driven by T2DM and obesity indications.
• The drug's success is supported by expanding indications, geographic expansion, and competitive advantages.
• Competition from tirzepatide and other emerging agents could alter market dynamics.
• Regulatory and reimbursement policies significantly influence future sales.
• The financial benefits for Novo Nordisk remain substantial, reinforcing its position in diabetes and weight management sectors.

FAQs

Q1: What factors have contributed most to OZEMPIC's recent sales growth?
The expansion into obesity management, increased prescriptions for T2DM, and broader geographic approval have driven sales.

Q2: How does OZEMPIC compare to its closest competitors?
In market share, OZEMPIC leads among GLP-1 receptor agonists, though tirzepatide (Mounjaro) shows promising efficacy and growth, potentially threatening OZEMPIC’s dominance.

Q3: What are the main regulatory challenges?
Pricing and reimbursement policies vary; some regions impose strict controls, affecting access and sales.

Q4: Will OZEMPIC sustain its growth trajectory?
Continued expansion into new markets, increasing obesity indication adoption, and competitive positioning suggest sustained growth, barring regulatory setbacks.

Q5: How critical is OZEMPIC to Novo Nordisk's overall revenue?
It accounts for approximately 30% of total sales, making it a cornerstone of the company's financial performance.

---

References

[1] Fortune Business Insights. (2023). Global GLP-1 receptor agonists market research report.